D
Spero Therapeutics, Inc.
SPRO
$0.60
$0.02253.90%
D
Sell
3/28/2025Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 3/28/2025 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 283.35% from $12.76M to -$23.4M, total capital declined 28.1% from $70.13M to $50.42M, and net income declined 21.82% from -$17.15M to -$20.89M.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 3/28/2025 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 283.35% from $12.76M to -$23.4M, total capital declined 28.1% from $70.13M to $50.42M, and net income declined 21.82% from -$17.15M to -$20.89M.
D
Sell
11/7/2024Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 11/7/2024 due to a decline in the total return index, efficiency index and valuation index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 11/7/2024 due to a decline in the total return index, efficiency index and valuation index.
D
Sell
10/23/2024Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 10/23/2024 due to an increase in the total return index, volatility index and valuation index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 10/23/2024 due to an increase in the total return index, volatility index and valuation index.
D
Sell
10/8/2024Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 10/8/2024 due to a decline in the total return index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 10/8/2024 due to a decline in the total return index.
D
Sell
9/16/2024Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 9/16/2024 due to an increase in the volatility index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 9/16/2024 due to an increase in the volatility index.
D
Sell
8/30/2024Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 8/30/2024 due to a decline in the volatility index, valuation index and total return index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 8/30/2024 due to a decline in the volatility index, valuation index and total return index.
D
Sell
8/15/2024Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 8/15/2024 due to a substantial increase in the growth index and total return index. Total revenue increased 10.04% from $9.27M to $10.2M.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 8/15/2024 due to a substantial increase in the growth index and total return index. Total revenue increased 10.04% from $9.27M to $10.2M.
D
Sell
5/28/2024Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 5/28/2024 due to a significant decline in the growth index, solvency index and total return index. EBIT declined 127.67% from $50.53M to -$13.98M, earnings per share declined from $0.9635 to -$0.24, and total revenue declined 87.4% from $73.52M to $9.27M.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 5/28/2024 due to a significant decline in the growth index, solvency index and total return index. EBIT declined 127.67% from $50.53M to -$13.98M, earnings per share declined from $0.9635 to -$0.24, and total revenue declined 87.4% from $73.52M to $9.27M.
D
Sell
4/17/2024Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D+ from C- on 4/17/2024 due to a noticeable decline in the solvency index and volatility index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D+ from C- on 4/17/2024 due to a noticeable decline in the solvency index and volatility index.
C
Hold
4/1/2024Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to C- from D+ on 4/1/2024 due to a noticeable increase in the solvency index, volatility index and total return index.
Spero Therapeutics, Inc. (SPRO) was upgraded to C- from D+ on 4/1/2024 due to a noticeable increase in the solvency index, volatility index and total return index.
D
Sell
3/18/2024Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D- on 3/18/2024 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 1,697.22% from -$3.21M to $51.19M, total capital increased 88.86% from $59.54M to $112.44M, and debt to equity declined from 0.03 to 0.02.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D- on 3/18/2024 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 1,697.22% from -$3.21M to $51.19M, total capital increased 88.86% from $59.54M to $112.44M, and debt to equity declined from 0.03 to 0.02.
D
Sell
3/1/2024Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 3/1/2024 due to an increase in the total return index and volatility index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 3/1/2024 due to an increase in the total return index and volatility index.
E
Sell
12/1/2023Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and valuation index.
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and valuation index.
D
Sell
11/16/2023Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 11/16/2023 due to an increase in the growth index, solvency index and volatility index. Total revenue increased 837.89% from $2.72M to $25.47M, operating cash flow increased 185.73% from -$18.56M to $15.92M, and EBIT increased 126.16% from -$12.89M to $3.37M.
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 11/16/2023 due to an increase in the growth index, solvency index and volatility index. Total revenue increased 837.89% from $2.72M to $25.47M, operating cash flow increased 185.73% from -$18.56M to $15.92M, and EBIT increased 126.16% from -$12.89M to $3.37M.
E
Sell
11/13/2023Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 11/13/2023 due to a decline in the total return index and volatility index.
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 11/13/2023 due to a decline in the total return index and volatility index.
D
Sell
10/25/2023Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 10/25/2023 due to a significant increase in the growth index, total return index and volatility index. Total revenue increased 31.27% from $2.07M to $2.72M, earnings per share increased from -$0.2526 to -$0.2266, and EBIT increased 9.4% from -$14.23M to -$12.89M.
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 10/25/2023 due to a significant increase in the growth index, total return index and volatility index. Total revenue increased 31.27% from $2.07M to $2.72M, earnings per share increased from -$0.2526 to -$0.2266, and EBIT increased 9.4% from -$14.23M to -$12.89M.
E
Sell
6/12/2023Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index and total return index.
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index and total return index.
D
Sell
5/25/2023Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 5/25/2023 due to an increase in the volatility index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 5/25/2023 due to an increase in the volatility index.
E
Sell
5/16/2023Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 5/16/2023 due to a decline in the volatility index, total return index and valuation index.
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 5/16/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/14/2023Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and volatility index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index.
D
Sell
12/6/2022Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 12/6/2022 due to an increase in the total return index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 12/6/2022 due to an increase in the total return index.
D
Sell
11/18/2022Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 11/18/2022 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.04 to 0.05, and the quick ratio declined from 3.3 to 3.17.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 11/18/2022 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.04 to 0.05, and the quick ratio declined from 3.3 to 3.17.
D
Sell
11/16/2022Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 11/16/2022 due to an increase in the total return index and volatility index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 11/16/2022 due to an increase in the total return index and volatility index.
D
Sell
8/15/2022Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 8/15/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 52.89% from -$30.21M to -$14.23M, operating cash flow increased 18.39% from -$28.22M to -$23.03M, and earnings per share increased from -$1.0068 to -$0.87.
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 8/15/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 52.89% from -$30.21M to -$14.23M, operating cash flow increased 18.39% from -$28.22M to -$23.03M, and earnings per share increased from -$1.0068 to -$0.87.
E
Sell
8/8/2022Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 8/8/2022 due to a decline in the volatility index and total return index.
Spero Therapeutics, Inc. (SPRO) was downgraded to E+ from D- on 8/8/2022 due to a decline in the volatility index and total return index.
D
Sell
5/17/2022Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 5/17/2022 due to a large decline in the growth index, total return index and solvency index. The quick ratio declined from 7.98 to 1.79, total revenue declined 24.6% from $2.74M to $2.07M, and earnings per share declined from -$0.9048 to -$1.0068.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 5/17/2022 due to a large decline in the growth index, total return index and solvency index. The quick ratio declined from 7.98 to 1.79, total revenue declined 24.6% from $2.74M to $2.07M, and earnings per share declined from -$0.9048 to -$1.0068.
D
Sell
5/5/2022Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, solvency index and growth index. Operating cash flow declined 452.28% from -$4.95M to -$27.35M, debt to equity increased from 0.01 to 0.02, and earnings per share declined from -$0.7009 to -$0.9048.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, solvency index and growth index. Operating cash flow declined 452.28% from -$4.95M to -$27.35M, debt to equity increased from 0.01 to 0.02, and earnings per share declined from -$0.7009 to -$0.9048.
D
Sell
3/15/2022Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 3/15/2022 due to a decline in the volatility index and total return index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 3/15/2022 due to a decline in the volatility index and total return index.
D
Sell
1/18/2022Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 1/18/2022 due to an increase in the valuation index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 1/18/2022 due to an increase in the valuation index.
D
Sell
1/3/2022Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 1/3/2022 due to a decline in the valuation index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 1/3/2022 due to a decline in the valuation index.
D
Sell
12/9/2021Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 12/9/2021 due to an increase in the valuation index and volatility index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 12/9/2021 due to an increase in the valuation index and volatility index.
D
Sell
11/11/2021Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 11/11/2021 due to an increase in the solvency index and total return index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 11/11/2021 due to an increase in the solvency index and total return index.
D
Sell
11/8/2021Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
8/6/2021Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 8/6/2021 due to a noticeable decline in the solvency index and valuation index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 8/6/2021 due to a noticeable decline in the solvency index and valuation index.
D
Sell
6/28/2021Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 6/28/2021 due to an increase in the valuation index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 6/28/2021 due to an increase in the valuation index.
D
Sell
6/11/2021Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 6/11/2021 due to a decline in the valuation index, volatility index and total return index.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 6/11/2021 due to a decline in the valuation index, volatility index and total return index.
D
Sell
12/2/2020Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 12/2/2020 due to a large increase in the solvency index, total return index and valuation index. The quick ratio increased from 4.11 to 7.82.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 12/2/2020 due to a large increase in the solvency index, total return index and valuation index. The quick ratio increased from 4.11 to 7.82.
D
Sell
10/23/2020Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 10/23/2020 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 4.14 to 4.11.
Spero Therapeutics, Inc. (SPRO) was downgraded to D from D+ on 10/23/2020 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 4.14 to 4.11.
D
Sell
8/3/2020Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 8/3/2020 due to a major increase in the total return index, volatility index and solvency index. The quick ratio increased from 3.46 to 4.14.
Spero Therapeutics, Inc. (SPRO) was upgraded to D+ from D on 8/3/2020 due to a major increase in the total return index, volatility index and solvency index. The quick ratio increased from 3.46 to 4.14.
D
Sell
5/1/2020Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, growth index and valuation index.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, growth index and valuation index.
D
Sell
10/21/2019Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 10/21/2019 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.2945 to -$0.7443, EBIT declined 139.68% from -$5.7M to -$13.65M, and total revenue declined 72.07% from $7.72M to $2.16M.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 10/21/2019 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.2945 to -$0.7443, EBIT declined 139.68% from -$5.7M to -$13.65M, and total revenue declined 72.07% from $7.72M to $2.16M.
D
Sell
5/15/2019Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 5/15/2019 due to an increase in the growth index, solvency index and total return index. Total revenue increased 356.15% from $1.69M to $7.72M, the quick ratio increased from 9.48 to 16.41, and earnings per share increased from -$0.5976 to -$0.2945.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 5/15/2019 due to an increase in the growth index, solvency index and total return index. Total revenue increased 356.15% from $1.69M to $7.72M, the quick ratio increased from 9.48 to 16.41, and earnings per share increased from -$0.5976 to -$0.2945.
D
Sell
3/29/2019Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 3/29/2019 due to a decline in the solvency index and valuation index. The quick ratio declined from 12.89 to 9.48.
Spero Therapeutics, Inc. (SPRO) was downgraded to D- from D on 3/29/2019 due to a decline in the solvency index and valuation index. The quick ratio declined from 12.89 to 9.48.
D
Sell
12/3/2018Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 12/3/2018 due to an increase in the growth index and solvency index. Total revenue increased 42.12% from $463 to $658, operating cash flow increased 36.19% from -$8.64M to -$5.51M, and the quick ratio increased from 10.49 to 12.89.
Spero Therapeutics, Inc. (SPRO) was upgraded to D from D- on 12/3/2018 due to an increase in the growth index and solvency index. Total revenue increased 42.12% from $463 to $658, operating cash flow increased 36.19% from -$8.64M to -$5.51M, and the quick ratio increased from 10.49 to 12.89.
D
Sell
8/1/2018Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 8/1/2018 due to an increase in the growth index and efficiency index. Earnings per share increased from -$1.5927 to -$0.7408, net income increased 23.21% from -$13.86M to -$10.64M, and EBIT increased 22.74% from -$14M to -$10.82M.
Spero Therapeutics, Inc. (SPRO) was upgraded to D- from E+ on 8/1/2018 due to an increase in the growth index and efficiency index. Earnings per share increased from -$1.5927 to -$0.7408, net income increased 23.21% from -$13.86M to -$10.64M, and EBIT increased 22.74% from -$14M to -$10.82M.
E
Sell
5/1/2018Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to E+ from E on 5/1/2018 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 3.77 to 11.06, earnings per share increased from -$36.0171 to -$1.5927, and total revenue increased 66.33% from $597 to $993.
Spero Therapeutics, Inc. (SPRO) was upgraded to E+ from E on 5/1/2018 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 3.77 to 11.06, earnings per share increased from -$36.0171 to -$1.5927, and total revenue increased 66.33% from $597 to $993.
E
Sell
3/12/2018Upgraded
Spero Therapeutics, Inc. (SPRO) was upgraded to E from E- on 3/12/2018 due to an increase in the volatility index.
Spero Therapeutics, Inc. (SPRO) was upgraded to E from E- on 3/12/2018 due to an increase in the volatility index.
E
Sell
2/14/2018Downgrade
Spero Therapeutics, Inc. (SPRO) was downgraded to E- from E on 2/14/2018 due to a large decline in the volatility index.
Spero Therapeutics, Inc. (SPRO) was downgraded to E- from E on 2/14/2018 due to a large decline in the volatility index.
E
Sell
1/30/2018None
Spero Therapeutics, Inc. (SPRO) was downgraded to E from U on 01/30/2018.
Spero Therapeutics, Inc. (SPRO) was downgraded to E from U on 01/30/2018.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
